Therapeutic Response

EGFR Exon 19 (Deletion) status confers therapeutic sensitivity to Bevacizumab in combination with Erlotinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Avastin (bevacizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized bevacizumab in combination with erlotinib for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating variants. This indication is based on JO25567, a randomized, open-label, multi-centre phase 2 study that defined EGFR activating variants as either exon 19 deletions or exon 21 p.L858R.